ABUS Logo

Arbutus Biopharma Corporation (ABUS) 

NASDAQ
Market Cap
$677.43M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
506 of 963
Rank in Industry
271 of 552

Largest Insider Buys in Sector

ABUS Stock Price History Chart

ABUS Stock Performance

About Arbutus Biopharma Corporation

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated N-acetylgalactosamine (GalNAc) delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include AB-161, an oral HBV RNA destabilizer to destabilize HBV RNA, which leads in the reduction of HBsAg and other viral proteins; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Talon Therapeutics, Inc.; Gritstone Oncology, Inc.; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd.; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate a triple combination of AB-729 for the treatment of chronic HBV infection. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Insider Activity of Arbutus Biopharma Corporation

Over the last 12 months, insiders at Arbutus Biopharma Corporation have bought $0 and sold $111,487 worth of Arbutus Biopharma Corporation stock.

On average, over the past 5 years, insiders at Arbutus Biopharma Corporation have bought $0 and sold $509,906 worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 2,000 shares for transaction amount of $13,900 was made by HENRIQUES RICHARD C JR (director) on 2015‑08‑24.

List of Insider Buy and Sell Transactions, Arbutus Biopharma Corporation

2024-08-14Saledirector
8,846
0.0048%
$3.69$32,6370.00%
2024-02-02SaleInterim President & CEO
10,164
0.0057%
$2.31$23,504+40.34%
2024-02-02SaleChief Scientific Officer
9,982
0.0056%
$2.31$23,083+40.34%
2024-02-02SaleChief Financial Officer
9,593
0.0054%
$2.31$22,184+40.34%
2024-02-02SaleChief Medical Officer
4,358
0.0024%
$2.31$10,078+40.34%
2021-12-01SaleChief Scientific Officer
200,000
0.218%
$5.09$1.02M-44.14%
2021-02-09SaleChief Business Officer
20,000
0.0239%
$5.00$100,000-25.28%
2020-12-14SaleChief Business Officer
40,000
0.0439%
$5.00$200,032-29.51%
2020-07-23SaleChief Business Officer
20,000
0.0203%
$5.01$100,200-46.45%
2018-08-13SaleChief Scientific Officer
4,250
0.0076%
$9.51$40,436-60.00%
2018-07-11SaleChief Scientific Officer
10,000
0.017%
$10.00$100,000-61.98%
2018-07-09SaleChief Scientific Officer
10,000
0.0183%
$8.91$89,060-53.41%
2018-07-06SaleChief Scientific Officer
10,000
0.0166%
$8.45$84,500-55.27%
2018-07-05SaleChief Scientific Officer
10,000
0.0167%
$8.40$84,000-54.73%
2018-07-03SaleChief Scientific Officer
10,000
0.0174%
$8.00$80,000-50.24%
2017-10-03SaleChief Scientific Officer
20,000
0.0392%
$8.00$160,000-21.85%
2017-08-15SaleChief Scientific Officer
60,000
0.1079%
$3.70$222,000+51.33%
2015-08-24Purchasedirector
2,000
0.004%
$6.95$13,900-39.25%

Insider Historical Profitability

<0.0001%
McElhaugh Michael J.Interim President & CEO
1504793
0.7941%
$3.5804
Sofia Michael J.Chief Scientific Officer
1485121
0.7837%
$3.58010
HASTINGS DAVID CChief Financial Officer
181907
0.096%
$3.5801
Sims KarenChief Medical Officer
125542
0.0663%
$3.5801
MANCHESTER KEITH Sdirector
46069
0.0243%
$3.5801
HENRIQUES RICHARD C JRdirector
1000
0.0005%
$3.5810<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Whitefort Capital Management Lp$33.18M6.8212.86M-2.54%-$864,067.8021.68
BlackRock$26.84M5.5110.4M+0.14%+$36,943.02<0.01
Morgan Stanley$22.78M4.688.83M+26.43%+$4.76M<0.01
Kairos Capital Management Lp$20.23M4.167.84M-13.27%-$3.1M9.69
The Vanguard Group$15.45M3.175.99M-0.02%-$2,518.08<0.0001
Woodline Partners LP$10.5M2.164.07M-13.76%-$1.68M0.09
Hudson Bay Capital Management LP$9.08M1.873.52M-14.96%-$1.6M0.06
Adage Capital Partners Gp L L C$7.74M1.593MNew+$7.74M0.01
FourWorld Capital Management$7.74M1.593M+175.06%+$4.93M11.09
Geode Capital Management$7.63M1.572.96M+5.01%+$364,315.37<0.01
State Street$6.74M1.382.61M+8.98%+$555,035.38<0.0001
Citadel Advisors LLC$5.15M1.062M+3.2%+$159,562.67<0.01
Advisor Group Holdings Inc$3.53M0.731.37M0%+$00.01
Centiva Capital$3.49M0.721.35M-4.78%-$175,027.180.11
Northern Trust$2.73M0.561.06M-1.09%-$29,971.86<0.0001
Corbin Capital Partners, L.P.$2.2M0.45853,304New+$2.2M15.21
Boothbay Fund Management LLC$1.58M0.32612,277+34.97%+$409,314.510.05
Wellington Management Company$1.16M0.24451,305New+$1.16M<0.0001
Kennedy Capital Management Inc$1.13M0.23436,506+12.72%+$127,103.650.02
BNY Mellon$1.05M0.22407,625-10.77%-$126,943.80<0.0001
Saba Capital Management, L.P.$963,527.000.2373,460New+$963,527.000.02
Charles Schwab$875,175.000.18339,215-2.9%-$26,168.95<0.0001
Bank of Montreal$872,431.000.18334,265-5.11%-$46,979.96<0.0001
Nuveen$758,922.000.16294,1560%+$0<0.0001
Millennium Management LLC$624,907.000.13242,212-84.25%-$3.34M<0.0001
Citigroup$585,371.000.12226,888+965.95%+$530,455.70<0.0001
Goldman Sachs$450,739.000.09174,705+38.01%+$124,136.73<0.0001
RhumbLine Advisers$439,779.000.09170,460+3.54%+$15,056.61<0.0001
Fidelity Investments$427,872.000.09165,842+0.3%+$1,284.84<0.0001
UBS$347,844.000.07134,823-3.68%-$13,281.86<0.0001
American Century Investments$325,632.000.07126,214+53.17%+$113,040.08<0.0001
Clear Harbor Asset Management$299,953.000.06116,261-16.52%-$59,339.930.03
Susquehanna Fundamental Investments Llc$265,544.000.06102,924New+$265,544.000.01
Lighthouse Investment Partners, LLC$255,562.000.0599,055New+$255,562.000.02
Two Sigma$252,623.000.0597,916-51.96%-$273,270.72<0.0001
AllianceBernstein$247,783.000.0596,0400%+$0<0.0001
Simplex Trading Llc$227,000.000.0588,130-15.63%-$42,061.840.01
Barclays$230,000.000.0589,186-58.7%-$326,891.10<0.0001
JPMorgan Chase$227,381.000.0588,132-23.68%-$70,555.40<0.0001
Royal Bank of Canada$188,000.000.0473,146-31.78%-$87,574.49<0.0001
Deutsche Bank$187,973.000.0472,858+9.49%+$16,290.07<0.0001
Bank of America$176,634.000.0468,463-25.54%-$60,598.86<0.0001
Group One Trading$170,195.000.0465,967+802.17%+$151,330.02<0.01
MetLife Investment Management$159,630.000.0361,872+4.9%+$7,458.79<0.01
American International Group$161,093.000.0362,439-0.85%-$1,382.88<0.01
Invesco$153,608.000.0359,538+5.05%+$7,391.70<0.0001
LMR PARTNERS LLP$154,800.000.0360,0000%+$0<0.01
The Manufacturers Life Insurance Company$137,081.000.0353,132+1.85%+$2,489.71<0.0001
Cowen Group$129,000.000.0350,0000%+$0<0.01
Voya Investment Management LLC$115,855.000.0244,905-20.23%-$29,381.06<0.0001
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.